Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan
By Chris Wack
Akili said that its Japanese partner, Shionogi & Co., has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
The digital medicine company said SDT-001 is the Japanese, localized version of its AKL-T01, marketed as EndeavorRx the U.S.
EndeavorRx has previously been authorized by the U.S. Food and Drug Administration as the world's first prescription digital therapeutic for improving attentional functioning in pediatric ADHD patients aged 8 to 17.
The submission for marketing approval in Japan is based on the favorable results of the Phase 3 clinical trial conducted by Shionogi. The trial aimed to evaluate the efficacy and safety of SDT-001 in 164 pediatric ADHD patients aged 6 to 17 who received conventional treatments such as environmental adjustments and psychosocial therapies.
No safety concerns or serious adverse events related to SDT-001 were observed, and symptom improvements were sustained even after two cycles of SDT-001 use, with no safety concerns noted.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 26, 2024 09:20 ET (14:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters